Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

yttrium Y 90 DOTA monoclonal antibody HuPAM4

Known as: Y90 DOTA MOAB HuPAM4, Yttrium Y-90 Clivatuzumab Tetraxetan, IMMU-107 
A radioimmunoconjugate comprised of the humanized monoclonal antibody clivatuzumab, directed against the pancreatic cancer antigen MUC1, that is… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
4043 Background: A Phase I/II trial evaluated single and repeated cycles of fractionated radioimmunotherapy (RAIT) with 90Y… Expand
Is this relevant?
Review
2012
Review
2012
Metastatic pancreatic cancer is an aggressive malignancy that is difficult to treat. Gemcitabine monotherapy has been used first… Expand
Is this relevant?
2012
2012
227 Background: A Phase I/II trial was undertaken to evaluate repeated cycles of 90Y-labeled anti-mucin humanized mAb (90Y-hPAM4… Expand
Is this relevant?
2011
2011
240 Background: The90Y-labeled anti-mucin humanized mAb, clivatuzumab tetraxetan (90Y-hPAM4), is in clinical development in APC… Expand
Is this relevant?
2010
2010
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC Background: A serum-based enzyme immunoassay (EIA… Expand
Is this relevant?
2010
2010
e14502 Background: A single dose of 90Y-labeled anti-mucin humanized mAb, clivatuzumab tetraxetan (90Y-hPAM4), showed transient… Expand
Is this relevant?
2009
2009
4620 Background: In a phase I study, a single dose of 90Y-labeled anti-mucin humanized antibody, hPAM4 (90Y-hPAM4), led to… Expand
Is this relevant?